DGAP-News

ERYTECH PHARMA SA: ERYTECH announces granting of new patent in the United States

DGAP-News: ERYTECH PHARMA SA / Key word(s): Patent
ERYTECH PHARMA SA: ERYTECH announces granting of new patent in the
United States

21.10.2014 / 11:24

---------------------------------------------------------------------

ERYTECH announces granting of new patent in the United States

- Patent that can strengthen positioning of ERY-ASP/GRASPA(R) by
detecting the presence of neutralizing antibodies to asparaginase

- Patent delivered in the USA with patent term until 2029

- Patent already granted in Europe, Australia and Singapore


Lyon (France), October 21, 2014 - ERYTECH (Euronext Paris: FR0011471135 -
ERYP), the French biopharmaceutical company that develops innovative 'tumor
starvation' treatments for acute leukemia and other oncology indications
with unmet medical needs, announces the granting of a new patent in the
field of asparaginase in the United States.

The patent 'Test for predicting neutralization of asparaginase activity'
(WO 2010/052315 A1) protects the process and methods for the detection of
factors neutralizing the activity of asparaginase in patients, notably
anti-asparaginase antibodies. A large percentage of patients treated with
current forms of asparaginases are known to develop neutralizing antibodies
to asparaginase, which drastically reduces its activity and treatment
efficacy. In addition, these patients have a higher chance to develop
hypersensitivity reactions, some of which can be severe. Detecting the
presence of these neutralizing factors before the administration of
asparaginase can reduce the risk of treatment inefficacy and allergic
reactions by enabling to propose the product with the best risk profile in
these conditions.

In the clinical studies with ERY-ASP/GRASPA(R), a very significant
reduction of allergic reactions and a sustained asparaginase activity have
been observed, even in the presence of antibodies, and this thanks to the
encapsulation of the asparaginase in red blood cells. Recent analysis of
the top-line Phase III results of the GRASPIVOTALL (GRASPALL2009-06) study
in relapsing Acute Lymphoblastic Leukemia (ALL) has shown favorable
results, also in patients who had prior allergies to L-asparaginase. In
patients without history of allergic reactions, none of the patients
developed allergies to GRASPA(R) versus 43% for the native
L-asparaginase. Only two of twenty-six patients with prior allergies to
L-asparaginase developed allergies to GRASPA(R) and these have been of mild
nature. In these patients the average duration of asparaginase activity